--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About BCAX20261016C35
Biotechnology Ⅲ
Bicara Therapeutics Inc. was incorporated under the laws of the State of Delaware on December 12, 2018. The company is a clinical-stage biopharmaceutical company focused on the development of bifunctional therapies for solid tumors. Its lead drug candidate, ficerafusp alfa, targets both the EGFR and TGF-β pathways and is currently in a pivotal trial for head and neck squamous cell carcinoma.
